Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our Science
- Our scientific strategy
- Our pipeline
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

News & Announcements

News & Announcements

Year

Apr 13, 2021

Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon

Mar 24, 2021

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results

Mar 22, 2021

Cerevel Therapeutics to Present at the Stifel 3rd Annual CNS Day Event

Feb 24, 2021

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021

Feb 23, 2021

Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference

Jan 28, 2021

Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs

Jan 21, 2021

Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
NewsroomNewsroom
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy

© 2021 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.